Adial Pharmaceuticals

Management exited the Purnovate subsidiary and focused resources on AD04, then executed a reverse split to maintain listing and in March 2026 signed a European commercialization framework for AD04 with Molteni.

In June 2026 they acquired Azora and raised new capital, which strategically broadens the pipeline into IBD but dramatically dilutes existing shareholders and triggers change‑of‑control dynamics. Prior reliance on ATMs and inducement warrant transactions highlights a history of dilution to fund operations.

While the pivot could create option value if AT177 validates, the track record of high‑return reinvestment is unproven and shareholder friendliness is mixed.